New learning discoveries about 220641-87-2

220641-87-2, The synthetic route of 220641-87-2 has been constantly updated, and we look forward to future research findings.

220641-87-2, N-Methyltetrahydro-2H-pyran-4-amine is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N- Methyltetrahydro-2H-pyran-4-amine (12.4 mg, 0.11 mmol) was added to a solution of (S)-isopropyl 2-(6-(bromomethyl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-4-(7- azaspiro[3.5]nonan-7-yl)pyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.036 mmol) and Hunig’s base (0.02 mL, 0.11 mmol) in abs. EtOH (0.5 mL) and the solution was stirred for 4 h at rt. UPLC (M+H) = 730.5. KOH (20.16 mg, 0.36 mmol) was added to the solution above and the temperature was raised to 80 C for 16 h. TFA (0.028 mL, 0.359 mmol) was added and the reaction mixture was concentrated. The crude product was purified by prep HPLC to obtain (S)-2-(tert-butoxy)-2-(5-(4-(4- fluorophenethoxy)phenyl)-2-methyl-6-((methyl(tetrahydro-2H-pyran-4- yl)amino)methyl)-4-(7-azaspiro[3.5]nonan-7-yl)pyridin-3-yl)acetic acid 8.3 mg (33%). 1H NMR (500 MHz, DMSO) delta 7.39-7.36 (m, 2H), 7.31 (d, J=8.4 Hz, 1H), 7.13 (t, J=9.1 Hz, 2H), 7.06-7.04 (m, 3H), 5.86 (s, 1H), 4.27-4.19 (m, 2H), 3.92-3.87 (m, 2H), 3.80 (d, J=14.8 Hz, 1H), 3.41 (br. s, 3H), 3.24 (t, J=9.9 Hz, 2H), 3.21-3.16 (m, 2H), 3.06 (t, J=6.2 Hz, 2H), 2.72/2.58 (s, 3H), 2.55 (s, 3H), 2.26 (br. s, 1H), 1.84-1.47 (series of m, 14H), 1.13 (s, 9H). UPLC (M+H) = 688.5.

220641-87-2, The synthetic route of 220641-87-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; KADOW, John F.; NAIDU, B. Narasimhulu; ROMINE, Jeffrey Lee; SIVAPRAKASAM, Prasanna; ST. LAURENT, Denis R.; (204 pag.)WO2017/25864; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Brief introduction of 185815-59-2

As the paragraph descriping shows that 185815-59-2 is playing an increasingly important role.

185815-59-2, 4-Isobutyldihydro-2H-pyran-2,6(3H)-dione is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,185815-59-2

A 100 ml three-necked round-bottom flask, under nitrogen atmosphere, is added with 98% hydrazine hydrate (19.5 g, 0.382 mols), sodium hydroxide (12.4 g, 0.309 mol) in water (150 ml) and the solution is cooled to a temperature of -5C. A solution of 3-isobutyl-glutaric anhydride (50.0 g, 0.294 mol) in toluene (200 ml) is dropped therein in about 1-2 h, keeping the temperature below 0-5C. The mixture is reacted for about 1 h, then the phases are separated, the aqueous phase is concentrated to small volume, thereby obtaining a white solid which is taken up into isopropanol (100 ml) and filtered. The solid is dried under vacuum at a temperature of 30-35C for 16-18 hours. 56.7 g of product are obtained, in an 86% yield. 1H-NMR (300 MHz, D2O, 28C): delta 2.20-1.90 (m, 5H); 1.50 (m, 1H); 1.05 (m, 2H); 0.75 (d, 6H).

As the paragraph descriping shows that 185815-59-2 is playing an increasingly important role.

Reference£º
Patent; Dipharma Francis S.r.l.; EP2067768; (2009); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Some tips on 25637-16-5

25637-16-5, 25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.

[00497] To a solution of 122-1 (50.0 mg, 0.16 mmol, 1. 0 eq) in DMF (5.0 mL) was added K2C03 (45.23 mg, 0.33 mmol, 2.0 eq) and 122-2 (32.4 mg, 0.120 mmol, 1.2 eq). The mixture was stirred at 100 C for 24 hours under an N2 atmosphere. LCMS showed the desired compound was formed. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give the title compound (27.33 mg, 70.19 umol, 42.85% yield). LCMS (ESI): RT = 0.932 min, mass calc. for Ci9Hi8F3N50 389.15, m/z found 390.0[M+H]+; 1HNMR (400 MHz, CDCl3-i 9.08 (s, 1H), 8.21 (dd, J= 1.4, 7.9 Hz, 1H), 7.54 (d, J= 8.5 Hz, 3H), 7.41- 7.35 (m, 1H), 7.29 (d, J= 8.5 Hz, 2H), 7.05 (t, J= 7.3Hz, 1H), 5.07 – 4.95 (m, 1H), 4.16 (td, J= 3.3, 12.0 Hz, 2H), 3.64 (dt, J = 2.3, 11.5 Hz, 2H), 2.46 – 2.24 (m, 4H).

25637-16-5, 25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; VIVACE THERAPEUTICS, INC.; KONRADI, Andrei W.; LIN, Tracy Tzu-Ling Tang; (396 pag.)WO2018/204532; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Downstream synthetic route of 344329-76-6

344329-76-6, As the paragraph descriping shows that 344329-76-6 is playing an increasingly important role.

344329-76-6, Tetrahydro-2H-pyran-4-carboxamide is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 17 A solution of Example B5 (0.103 g, 0.800 mmol) in DCE (3 mL) was treated with oxalyl chloride (0.070 mL, 0.800 mmol) and heated at 80¡ã C. for 4 h. The mixture was cooled to RT, added to a solution of Example A6 (0.09 g, 0.320 mmol) and TEA (0.129 g, 1.280 mmol) in DCM (2 mL) and stirred at RT overnight. The mixture was concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford N-((6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)tetrahydro-2H-pyran-4-carboxamide (88 mg, 63percent) as a white solid. 1H NMR (400 MHz, DMSO-d6): delta 11.00 (s, 1H), 10.87 (s, 1H), 8.35 (d, J=5.7 Hz, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 6.60 (dd, J=5.7, 2.4 Hz, 1H), 3.89-3.87 (m, 2H), 3.84 (s, 3H), 3.32-3.28 (m, 2H), 2.70-2.67 (m, 1H), 2.25 (s, 3H), 1.72 (d, J=12.9 Hz, 2H), 1.61-1.58 (m, 2H); MS (ESI) m/z: 437.2 (M+H+).

344329-76-6, As the paragraph descriping shows that 344329-76-6 is playing an increasingly important role.

Reference£º
Patent; Deciphera Pharmaceuticals, LLC; Flynn, Daniel L.; Caldwell, Timothy Malcolm; Kaufman, Michael D.; Patt, William C.; Samarakoon, Thiwanka; Vogeti, Lakshminarayana; Yates, Karen M.; US2014/275080; (2014); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Simple exploration of 137052-08-5

137052-08-5, The synthetic route of 137052-08-5 has been constantly updated, and we look forward to future research findings.

137052-08-5, 1-(Tetrahydro-2H-pyran-4-yl)ethanone is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

First add 1- (tetrahydro-2H-pyran-4-yl) ethanone (10g, 78.02mmol) to 50mL of methanol,After cooling to -10 C, liquid bromine (4.0 mL, 78.02 mmol) was added to the reaction under an argon atmosphere.It was then reacted at 0 C for 45 min, followed by 10 C for 45 min.Sulfuric acid (27.5mL, 11M) was added to the above system, returned to room temperature and stirred overnight.After the reaction was completed, saturated brine and ethyl acetate were added for extraction, and the organic phases were combined, washed sequentially with saturated sodium bicarbonate solution and water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title product.

137052-08-5, The synthetic route of 137052-08-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Nanjing Shenghe Pharmaceutical Co., Ltd.; Wang Yong; Zhao Liwen; Wang Yazhou; Zhang Yan; Wang Xiaowei; Wang Hai; Guo Zhuang; Lv Kunzhi; Chang Yujie; Chen Hongyan; Xu Guofeng; (37 pag.)CN111072645; (2020); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Analyzing the synthesis route of 110238-91-0

As the paragraph descriping shows that 110238-91-0 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110238-91-0,Methyl tetrahydro-2H-pyran-4-carboxylate,as a common compound, the synthetic route is as follows.

A solution of methyl tetrahydro-2H-pyran-4-carboxylate (5 g, 34.6 mmol) in anhydrous diethyl ether was chilled in an ice bath and 1 M LiAlH4 in diethyl ether (52 mL, 51.9 mmol) was added dropwise under an N2 atmosphere. The reaction was allowed to warm to room temperature with stirring overnight. The reaction was quenched by slowly adding 1 N aqueous NaOH (3 mL). The slurry was filtered through a pad of Celite. The Celite pad was rinsed with diethyl ether followed by methanol and the solution was dried in vacuo to yield (tetrahydro-2H- pyran-4-yl)methanol (4 g, 34.6 mmol) as a clear oil. [M+eta] calc’d for C6H]2O2, 117; found, 117., 110238-91-0

As the paragraph descriping shows that 110238-91-0 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; WO2009/97578; (2009); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Downstream synthetic route of 4677-20-7

As the paragraph descriping shows that 4677-20-7 is playing an increasingly important role.

4677-20-7, 4-(2-Bromoethyl)tetrahydropyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7: 6-Amino-2-butylamino-9-r2-(tetrahvdro-2H-pyran-4-yl)ethyll-7,9-dihvdro- 8H-purin-8-one To a solution of /V2-butyl-8-methoxy-9H-purine-2,6-diamine trifluoroacetic acid salt (100 mg) in dry N,N-dimethylformamide (1 ml) at room temperature and under nitrogen was added potassium carbonate (158 mg) in one go. The reaction was stirred at 6O C for 1.5 hours and then cooled to 5O C. A solution of 4-(2- bromoethyl)tetrahydro-2H-pyran (60 mg) in dry N,N-dimethylformamide (0.5 ml) was added in one go and the reaction heated at 5O C overnight. The reaction was diluted with ethyl acetate (15 ml) and washed with water (5 ml). The organic layer was separated and concentrated in vacuo. The product was purified by C18 reverse phase chromatography using water (0.1% formic acid)-acetonitrile (0.05% formic acid) as eluant (20-60%) to afford a yellow viscous oil (47mg) that was dissolved in dry methanol (4 ml) at room temperature and under nitrogen was added 4.0M hydrogen chloride in 1 ,4-dioxane (0.8 ml) in one go. The reaction was left to stir at room temperature overnight. The reaction was neutralised by the addition of 2.0M sodium hydroxide solution and concentrated in vacuo. The residue was taken up in water (5 ml) and the solid filtered and dried in vacuo (60C) for 30 minutes. This afforded the title compound as a beige solid (23mg). MS calcd for (C16H26N6O2)+ = 334 MS found (electrospray): (M+H)+ =3351H NMR ((CDa)2SO): delta 9.78 (1 H, s), 6.08-6.21 (3H, br. s), 3.80 (2H, m), 3.65 (2H, t), 3.21 (2H, m), 3.16 (2H, m), 1.66 (2H, m), 1.57 (2H, m), 1.36-1.49 (3H, m), 1.29 (2H, m), 1.13 (2H, m), 0.88 (3H, t)., 4677-20-7

As the paragraph descriping shows that 4677-20-7 is playing an increasingly important role.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/101867; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

New learning discoveries about 287193-07-1

As the paragraph descriping shows that 287193-07-1 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.287193-07-1,Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate,as a common compound, the synthetic route is as follows.

To a solution of 4-oxo-tetrahydro-2H-pyran-2-carboxylic acid ethyl (0.6 g, 3.5 mmol) in absolute ethanol (6 ml) was added sulfur (0.12 g, 3.85 mmol) and tert-butyl cyanoacetate (0.64 g, 4.55 mmol). The solution was stirred under nitrogen in a 50 C. oil bath and morpholin (0.61 ml, 7.0 mmol) was added. The reaction was stirred for 18 hours and then cooled to ambient temperature and excess sulfur removed by filtration. The filtrate was concentrated in vacuo and reconstituted in ethyl acetate (50 ml). The organic phase was washed with brine (2*10 ml), dried (Na2SO4), filtered, and the solvent evaporated in vacuo. The residue was purified by silica gel chromatography using a gradient of ethyl acetate/hexane (20 to 25% gradient) as eluent. Pure fraction of the two isomers were collected and the solvent evaporated in vacuo which afforded 0.47 g of 2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3,5-dicarboxylic acid 3-tert-butyl ester 5-ethyl ester (A) and 0.3 g of 2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3,7-dicarboxylic acid 3-tert-butyl ester 7-ethyl ester (B) in 62% combined yield. (A)1H-NMR (300 MHz, CDCl3) delta 5.96 (bs, 2H), 4.77-4.61 (m, 2H), 4.32-4.18 (m, 3H), 3.19-3.12 (m, 1H), 2.90-2.80 (m, 1H), 1.52 (s, 9H), 1.29 (t, 3H, J=7 Hz).(B)1H-NMR (300 MHz, CDCl3) delta 5.10 (s, 1H), 4.28-4.13 (m, 3H), 3.98-3.91 (m, 1H), 2.82-2.76 (m, 2H), 1.51 (s, 9H), 1.31 (t, 3H, J=7 Hz)., 287193-07-1

As the paragraph descriping shows that 287193-07-1 is playing an increasingly important role.

Reference£º
Patent; Novo Nordisk A/S; US7019026; (2006); B1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Brief introduction of 4295-99-2

4295-99-2, The synthetic route of 4295-99-2 has been constantly updated, and we look forward to future research findings.

4295-99-2, 4-Cyanotetrahydro-4H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of tetrahydro-2H-pyran-4-carbonitrile (2 g, 18.00 mmol) in tetrahydrofuran (10 mL) at 0 – 5 C was added slowly LHMDS (21.59 mL, 21.59 mmol). The mixture was stirred for 1.5 hrs at 0 C. lodomethane (3.37 mL, 54.0 mmol) was added slowly and stirring was continued for 30 min at ~0 C and then for ~2 hrs at room temperature. The mixture was cooled to 0 C and carefully diluted with IN aqueous hydrochloride solution (30 mL) and EtOAc (5 mL) and concentrated under reduced pressure. The residue was taken up in diethylether and the separated organic layer was washed with brine, dried over sodium sulfate, filtered off and concentrated under reduced pressure providing crude 4-methyltetrahydro-2H-pyran-4-carbonitrile (1.8 g) as an orange oil, which was directly used in the next reaction without further purification. LCMS (m/z): 126.1 [M+H]+; Retention time = 0.44 min.

4295-99-2, The synthetic route of 4295-99-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; ANTONIOS-MCCREA, William R.; BARSANTI, Paul A.; HU, Cheng; JIN, Xianming; MARTIN, Eric J.; PAN, Yue; PFISTER, Keith B.; SENDZIK, Martin; SUTTON, James; WAN, Lifeng; WO2012/66065; (2012); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Analyzing the synthesis route of 1768-64-5

As the paragraph descriping shows that 1768-64-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1768-64-5,4-Chlorotetrahydropyran,as a common compound, the synthetic route is as follows.

To a vigorously stirred suspension of Mg (1.76 g, 72.8 mmol) turnings and iodine (46.1 mg, 0.182 mmol) in THF (2 mL) under N2 was added 1,2-dibromoethane (68.3 mg, 0.364 mmol) and 10% of a solution of 4-chlorotetrahydro-2H-pyran (4.4 g, 36.4 mmol) in THF (18 mL). Themixture was heated to 60C and as the reaction mixture turned clear and Grignard initiatedtook place, the remainder of the solution of 4-chlorotetrahydro-2H-pyran in THF was added slowly over 30 mm. The reaction mixture was stirred at 65C for 2h to give a solution of (tetrahydro2H-pyran-4-yl)magnesium chloride in THF (-2M). The Grignard solution was used without any further purification. The solution of 36-4 (800 mg, 2.06 mmol) in THF (150 mL) under N2 wasadded to Grignard reagent at 15C in one portion. After stirring at 15C for 2 mm, the mixture was quenched by 200 mL of sat.NH4C1 and extracted with 200 mL of EtOAc. The separated organic phase was washed with 200 mL of brine, dried over Na2504, filtered and concentrated. The residue was purified by Combi-flash (0%-30% of EtOAc in PE/DCM(v/v=1/1)) to afford 36-5 (550 mg, 56%) as off-white solid, and 50 mg of 36-5 was delivered. ?H NMR (400 MHz,CDC13) 5.32-5.25 (m, 1H), 4.06-3.96 (m, 2H), 3.42-3.29 (m, 3H), 2.39-2.33 (m, 1H), 2.07-1.79(m, 6H), 1.77-1.60 (m, 7H), 1.5 1-1.38 (m, 1OH), 1.35-1.21 (m, 4H), 1.16-1.01 (m, 8H), 0.97-0.90(m, 4H), 0.85 (t, J = 7.4 Hz, 3H), 0.71-0.66 (m, 3H). LCMS Rt = 1.212 mm in 2 mmchromatography, 30-9OAB_2MIN_E.M, MS ESI calcd. for C31H5102 [M+H-H2Oj 455, found455., 1768-64-5

As the paragraph descriping shows that 1768-64-5 is playing an increasingly important role.

Reference£º
Patent; SAGE THERAPEUTICS, INC.; SALITURO, Francesco, G.; ROBICHAUD, Albert, Jean; MARTINEZ BOTELLA, Gabriel; HARRISON, Boyd, L.; (157 pag.)WO2017/7840; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics